Hims and Hers Expands Consumer-Focused Digital Health Platform

Core Insights - Hims & Hers Health, Inc. (HIMS) is developing a consumer-first digital health platform that integrates telehealth consultations, electronic medical records, digital prescriptions, and pharmacy fulfillment to enhance access to personalized care [1] - The company has expanded its offerings to include new specialties in men's health and women's health, as well as a new Labs feature for tracking biomarkers [2] - HIMS is also scaling its global presence by entering Canada, expanding its weight-loss program in the U.K., and planning to acquire Eucalyptus to strengthen its international market position [3] Company Developments - Hims & Hers has introduced low testosterone treatments and menopause services, addressing previously underserved health needs [2] - The launch of Labs allows customers to monitor key health metrics and receive tailored action plans from healthcare professionals [2] - The company is focused on continuous patient engagement through its subscription-based model, which supports personalized treatment plans [1] Financial Performance - Hims & Hers shares have decreased by 33.6% over the past year, underperforming the industry average decline of 23.6% [6] - The Zacks Consensus Estimate for HIMS' earnings per share in 2026 suggests no growth compared to 2025 [8] - HIMS' forward 12-month price-to-sales ratio is 1.8X, lower than the industry average of 3.5X and its five-year median of 2.7X, indicating potential undervaluation [9] Earnings Estimates - The current Zacks Consensus Estimates for HIMS' earnings per share are 0.02 for the current quarter, 0.12 for the next quarter, 0.53 for the current year, and 0.72 for the next year [11] - Year-over-year growth estimates show a significant decline of 90% for the current quarter and a 29.41% decline for the next quarter, with a projected growth of 35.65% for the next year [11]